RAVASIO, R.; TISEO, M.; PRADELLI, L.; BELLONE, M.; GERVASI, A.; COFFANI, M. Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Global and Regional Health Technology Assessment, [S. l.], v. 6, n. 1, 2019. DOI: 10.33393/grhta.2019.462. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/462. Acesso em: 3 jul. 2024.